The report also revealed that 87% of physicians agreed that FEE recommendations would help to improve the speed of recovery
Acquisition to advance company's next generation biology portfolio with internationally recognized pioneer in organoid development
Demonstrates vision gains with extended treatment intervals in retinal vein occlusion
The TGA approval marks a pivotal step in Rusan Pharma’s expansion into the Australian market
An investigational long-acting monoclonal antibody designed to protect infants from RSV disease during their first RSV season
A 40 minute daily Yoga routine, incorporating select asanas and pranayama, along with standard lifestyle interventions, can reduce the risk of developing diabetes by approximately 40%
Harnessing advanced data analysis for early detection, prevention and better outcomes
IBRANCE is the first CDK4/6 inhibitor to show benefit in a large Phase 3 trial in first-line HR+, HER2+ metastatic breast cancer, in combination with anti-HER2 and endocrine therapy
Acquisition adds potential best-in-class disease-modifying therapy for Alzheimer's disease
Vepdegestrant in combination with abemaciclib demonstrated encouraging clinical activity (clinical benefit rate
Subscribe To Our Newsletter & Stay Updated
